Targeting ATR in DNA damage response and cancer therapeutics.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Treatment Reviews

• Publication date

  2014-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ctrv.2013.03.002PMID 23583268
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.

  2013cited by this paper
• Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

  2012cited by this paper
• DNA Damage Repair Pathways in Cancer Stem Cells

  2012cited by this paper
• Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR.

  2012cited by this paper
• Cancer stem cells as a predictive factor in radiotherapy.

  2012cited by this paper
• The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

  2012cited by this paper
• Hypoxia Activates Tumor Suppressor p53 by Inducing ATR-Chk1 Kinase Cascade-mediated Phosphorylation and Consequent 14-3-3γ Inactivation of MDMX Protein*

  2012cited by this paper
• Abstract 1823: AZ20, a novel potent and selective inhibitor of ATR kinase with in vivo antitumour activity

  2012cited by this paper
• Targeting radiation-resistant hypoxic tumour cells through ATR inhibition

  2012cited by this paper
• Thresholds of replication stress signaling in cancer development and treatment

  2012cited by this paper
• ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres

  2012cited by this paper
• The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies

  2012cited by this paper
• Balancing repair and tolerance of DNA damage caused by alkylating agents

  2012cited by this paper
• DNA repair dysregulation from cancer driver to therapeutic target

  2012cited by this paper
• A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

  2011cited by this paper
• ATR-p53 Restricts Homologous Recombination in Response to Replicative Stress but Does Not Limit DNA Interstrand Crosslink Repair in Lung Cancer Cells

  2011cited by this paper
• Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.

  2011cited by this paper
• ATR autophosphorylation as a molecular switch for checkpoint activation.

  2011cited by this paper
• Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy

  2011cited by this paper
• Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

  2011cited by this paper
• Cancer Stem Cells: Targets and Potential Biomarkers for Radiotherapy

  2011cited by this paper
• Cancer Stem Cells and Chemosensitivity

  2011cited by this paper
• The role of PARP in DNA repair and its therapeutic exploitation

  2011cited by this paper
• Molecular mechanisms and clinical applications of angiogenesis

  2011cited by this paper
• Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

  2011cited by this paper
• Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.

  2011cited by this paper
• Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs

  2011cited by this paper
• Inhibition of Ataxia Telangiectasia‐ and Rad3 ‐Related Function Abrogates the In Vitro and In Vivo Tumorigenicity of Human Colon Cancer Cells Through Depletion of the CD133+ Tumor‐Initiating Cell Fraction

  2011cited by this paper
• Thr-1989 Phosphorylation Is a Marker of Active Ataxia Telangiectasia-mutated and Rad3-related (ATR) Kinase*

  2011cited by this paper
• Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.

  2011cited by this paper
• Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

  2011cited by this paper
• Maintaining genome stability at the replication fork

  2010cited by this paper
• Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

  2010cited by this paper
• Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.

  2010cited by this paper
• Tipin-Replication Protein A Interaction Mediates Chk1 Phosphorylation by ATR in Response to Genotoxic Stress*

  2010cited by this paper
• Epigenetic Modifications in Double-Strand Break DNA Damage Signaling and Repair

  2010cited by this paper
• Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells

  2010cited by this paper
• New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

  2010cited by this paper
• In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762

  2010cited by this paper
• A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

  2010cited by this paper
• ATR mediates cisplatin resistance in a p53 genotype-specific manner

  2010cited by this paper
• Advanced pancreatic carcinoma: current treatment and future challenges

  2010cited by this paper
• The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

  2010cited by this paper
• Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents

  2010cited by this paper
• The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

  2010cited by this paper
• Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.

  2010cited by this paper
• A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors.

  2010cited by this paper
• Pancreatic cancer.

  2010cited by this paper
• The ATR barrier to replication-born DNA damage.

  2010cited by this paper
• Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival

  2009cited by this paper
• The DNA-damage response in human biology and disease

  2009cited by this paper
• Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells.

  2009cited by this paper
• Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response

  2009cited by this paper
• A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging

  2009cited by this paper
• ATR and H2AX Cooperate in Maintaining Genome Stability under Replication Stress*

  2009cited by this paper
• Comparative Analysis of DNA Repair in Stem and Nonstem Glioma Cell Cultures

  2009cited by this paper
• Radiosensitization by Chir-124, a selective Chk1 inhibitor: Effects of p53 and cell cycle checkpoints

  2009cited by this paper
• The combined status of ATM and p53 link tumor development with therapeutic response.

  2009cited by this paper
• Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin

  2009cited by this paper
• Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

  2009cited by this paper
• Tissue regenerative delays and synthetic lethality in adult mice upon combined deletion of ATR and p53

  2009cited by this paper
• Principles of cancer therapy: oncogene and non-oncogene addiction.

  2009cited by this paper
• PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts

  2009cited by this paper
• Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis

  2009cited by this paper
• Activation of ATR and related PIKKs

  2008cited by this paper
• AKT Is Activated in an Ataxia-Telangiectasia and Rad3-Related-Dependent Manner in Response to Temozolomide and Confers Protection against Drug-Induced Cell Growth Inhibition

  2008cited by this paper
• ATR signaling can drive cells into senescence in the absence of DNA breaks.

  2008cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• An Oncogene-Induced DNA Damage Model for Cancer Development

  2008cited by this paper
• Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation.

  2008cited by this paper
• ATR: an essential regulator of genome integrity

  2008cited by this paper
• Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil

  2008cited by this paper
• Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

  2008cited by this paper
• Targeted cancer therapies based on the inhibition of DNA strand break repair

  2007cited by this paper
• The DNA damage response: ten years after.

  2007cited by this paper
• Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation

  2007cited by this paper
• DNA damage signalling guards against activated oncogenes and tumour progression

  2007cited by this paper
• Different S/M checkpoint responses of tumor and non tumor cell lines to DNA replication inhibition.

  2007cited by this paper
• Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo

  2007cited by this paper
• Loss of ataxia telangiectasia mutated– and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival

  2007cited by this paper
• The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1.

  2007cited by this paper
• Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

  2007cited by this paper
• Patterns of somatic mutation in human cancer genomes

  2007cited by this paper
• Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss.

  2007cited by this paper
• Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

  2006cited by this paper
• The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

  2006cited by this paper
• Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850)

  2006cited by this paper
• TopBP1 activates the ATR-ATRIP complex.

  2006cited by this paper
• Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy.

  2006cited by this paper
• Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

  2006cited by this paper
• Topoisomerase I inhibitors: camptothecins and beyond

  2006cited by this paper
• The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons*

  2005cited by this paper
• RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells.

  2005cited by this paper
• Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival

  2005cited by this paper
• The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms.

  2005cited by this paper
• Chk1 is Essential for Tumor Cell Viability Following Activation of the Replication Checkpoint

  2005cited by this paper
• A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.

  2005cited by this paper
• Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

  2004cited by this paper
• DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.

  2004cited by this paper
• Inhibition of ATR Leads to Increased Sensitivity to Hypoxia/Reoxygenation

  2004cited by this paper

• ATR Blockade Potentiates the Effects of Genotoxic Agents In Vitro and Promotes Antitumor Immunity in a Mouse Model of Non-Small Cell Lung Cancer

  2026cites this paper
• Targeting ATR in Cancer therapy: A drug discovery perspective.

  2026cites this paper
• Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313)

  2025cites this paper
• Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm

  2025cites this paper
• Downregulation of lncRNA H19 Enhances Radiosensitivity in Colorectal Cancer by Inactivation of the ATR/CHK1 Signaling

  2025cites this paper
• Kanser Tedavisinde PI3K/AKT/mTOR Yolunun Hedeflenmesi: Yeni Nesil mTOR İnhibitörlerine Güncel Bir Değerlendirme

  2025cites this paper
• Mapping Cophosphoregulation Networks Linked to Transcriptional Regulator Bromodomain-Containing Protein 4

  2025influential citation
• Feedforward miR-181d degradation modulates population variance of methyl-guanine methyl transferase and temozolomide resistance

  2025cites this paper
• Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)

  2025cites this paper
• Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates.

  2025cites this paper
• Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor.

  2025cites this paper
• Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics

  2025cites this paper
• sTPLS: identifying common and specific correlated patterns under multiple biological conditions

  2025cites this paper
• DNA repair mechanisms and their therapeutic implications in oral cancer

  2025cites this paper
• Modulating populational variance of methyl-guanine methyl transferase expression through miR-181d degradation: a novel mechanism of temozolomide resistance

  2025cites this paper
• Phase 1 clinical trial of the ataxia telangiectasia and Rad3‐related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)

  2025cites this paper
• Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors

  2024cites this paper
• The bioinformatics analysis and experimental validation of the carcinogenic role of EXO1 in lung adenocarcinoma

  2024cites this paper
• Targeting the DNA damage response in cancer

  2024cites this paper
• Isovalerylspiramycin I suppresses small cell lung cancer proliferation via ATR/CHK1 mediated DNA damage response and PERK/eIF2α/ATF4/CHOP mediated ER stress.

  2024cites this paper
• ATM and ATR gene editing mediated by CRISPR/Cas9 in Chinese Hamster cells.

  2024cites this paper
• Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors.

  2024cites this paper
• Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes

  2024cites this paper
• Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment.

  2024cites this paper
• Detecting Gene-Gene Interaction among DNA Repair Genes in Chinese non-Syndromic Cleft lip with or Without Palate Trios

  2024cites this paper
• Targeting ATR in Cancer Medicine.

  2023cites this paper
• Update on Emerging Therapies for Advanced Colorectal Cancer.

  2023cites this paper
• The p38/MK2 Pathway Functions as Chk1-Backup Downstream of ATM/ATR in G2-Checkpoint Activation in Cells Exposed to Ionizing Radiation

  2023cites this paper
• The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer

  2023cites this paper
• Hafnium oxide nanoparticles coated ATR inhibitor to enhance the radiotherapy and potentiate antitumor immune response

  2023cites this paper
• Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy

  2023cites this paper
• Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity

  2023cites this paper
• APOBEC3B coordinates R-loop to promote replication stress and sensitize cancer cells to ATR/Chk1 inhibitors

  2023cites this paper
• Molecular targets and mechanisms of anti-cancer effects of withanolides.

  2023cites this paper
• Reduction of HIF-1α/PD-L1 by Catalytic Topoisomerase Inhibitor Induces Cell Death Through Caspase Activation in Cancer Cells Under Hypoxia

  2023cites this paper
• Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis

  2023cites this paper
• Enhancer-driven transcription of MCM8 by E2F4 promotes ATR pathway activation and glioma stem cell characteristics

  2023cites this paper
• Biological Effects of Secondary Plant Metabolites on the Expression of Key Factors Involved in DNA Damage Response Signaling Pathway and Apoptosis in Cancer Cell Lines

  2023cites this paper
• Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors.

  2023cites this paper
• Pectolinarigenin inhibits bladder urothelial carcinoma cell proliferation by regulating DNA damage/autophagy pathways

  2023cites this paper
• ATR Inhibition in Advanced Urothelial Carcinoma

  2022influential citation
• Benzothiazole and Chromone Derivatives as Potential ATR Kinase Inhibitors and Anticancer Agents

  2022cites this paper
• Therapeutic targeting of ATR in alveolar rhabdomyosarcoma

  2022cites this paper
• Prevention of anticancer therapy-induced neurotoxicity: putting DNA damage in perspective.

  2022cites this paper
• Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice

  2022cites this paper
• Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity

  2022cites this paper
• SND1 Promotes Radioresistance in Cervical Cancer Cells by Targeting the DNA Damage Response

  2022cites this paper
• Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies

  2022cites this paper
• CRISPR screens guide the way for PARP and ATR inhibitor biomarker discovery

  2021cites this paper
• The cross-talk between signaling pathways, noncoding RNAs and DNA damage response: Emerging players in cancer progression.

  2021cites this paper
• Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer

  2021cites this paper
• The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.

  2021cites this paper
• Suppression of TopBP1 function increases the efficacy of chemotherapeutic treatments by enhancing the induction of apoptosis

  2021cites this paper
• DNA damage response and repair in pancreatic cancer development and therapy.

  2021cites this paper
• SETD2-mediated H3K14 trimethylation promotes ATR activation and stalled replication fork restart in response to DNA replication stress

  2021cites this paper
• Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?

  2021cites this paper
• Genetic vulnerabilities upon inhibition of DNA damage response

  2021cites this paper
• Targeting DNA damage repair pathways in pancreas cancer

  2021cites this paper
• A double-edged sword: The Kelch-like ECH-associated protein 1-nuclear factor erythroid-derived 2-related factor 2-antioxidant response element pathway targeted pharmacological modulation in nonalcoholic fatty liver disease.

  2021cites this paper
• Integrating SNPs-based genetic risk factor with blood epigenomic response of differentially arsenic-exposed rural subjects reveals disease-associated signaling pathways.

  2021cites this paper
• ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide

  2021cites this paper
• Cell cycle control and DNA-damage signaling in mammals

  2021cites this paper
• Modulating CRISPR/Cas9 genome-editing activity by small molecules.

  2021cites this paper
• Multiple Genotoxic Agents Activate ATR Kinase Signaling in Quiescent Human Cells

  2021influential citation
• ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer

  2020influential citation
• Exploiting a PAX3-FOXO1-induced synthetic lethal ATR dependency for rhabdomyosarcoma therapy

  2020cites this paper
• Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitors

  2020cites this paper
• OTT_A_227015 225..235

  2020cites this paper
• MicroRNA-708 Suppresses Cell Proliferation and Enhances Chemosensitivity of Cervical Cancer Cells to cDDP by Negatively Targeting Timeless

  2020cites this paper
• DNA damage response proteins and its role in tumor progression of uveal melanoma with patient outcome

  2020cites this paper
• Genome-wide CRISPR synthetic lethality screen identifies a role for the ADP-ribosyltransferase PARP14 in replication fork stability controlled by ATR

  2020cites this paper
• Dual genome-wide CRISPR knockout and CRISPR activation screens identify common mechanisms that regulate the resistance to multiple ATR inhibitors

  2020cites this paper
• Phosphorylation-Dependent Pin1 Isomerization of ATR: Its Role in Regulating ATR’s Anti-apoptotic Function at Mitochondria, and the Implications in Cancer

  2020cites this paper
• ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status

  2020cites this paper
• Single-molecule imaging of telomerase RNA reveals a Recruitment – Retention model for telomere elongation

  2020cites this paper
• Genome-wide CRISPR synthetic lethality screen identifies a role for the ADP-ribosyltransferase PARP14 in DNA replication dynamics controlled by ATR

  2020cites this paper
• A Comprehensive Review and Perspective on Anticancer Mechanisms of Withaferin A in Breast Cancer

  2020cites this paper
• Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting

  2020cites this paper
• Identification of key gene modules and genes in colorectal cancer by co-expression analysis weighted gene co-expression network analysis

  2020cites this paper
• Harnessing DNA Replication Stress for Novel Cancer Therapy

  2020cites this paper
• Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor.

  2020cites this paper
• A novel iron(II) phenanthroline complex exhibits anticancer activity against TFR1-overexpressing esophageal squamous cell carcinoma cells through ROS accumulation and DNA damage.

  2019cites this paper
• OTT_A_209907 4403..4413

  2019cites this paper
• Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers

  2019cites this paper
• Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells

  2019cites this paper
• Radiation-dose-dependent functional synergisms between ATM, ATR and DNA-PKcs in checkpoint control and resection in G2-phase

  2019cites this paper
• Norcantharidin inhibits the DDR of bladder cancer stem-like cells through cdc6 degradation

  2019cites this paper
• Preclinical Combination Studies of an FGFR2 Targeted Thorium Conjugate and the ATR Inhibitor BAY 1895344.

  2019cites this paper
• DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies.

  2019cites this paper
• GSK3-β Stimulates Claspin Degradation via β-TrCP Ubiquitin Ligase and Alters Cancer Cell Survival

  2019cites this paper
• Molecular Carcinogenesis

  2019influential citation
• Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.

  2019cites this paper
• Polyphenols: Major regulators of key components of DNA damage response in cancer.

  2019cites this paper
• ATR Kinase Activity Limits Mutagenesis and Promotes the Clonogenic Survival of Quiescent Human Keratinocytes Exposed to UVB Radiation

  2019cites this paper
• ATR kinase inhibition sensitizes quiescent human cells to the lethal effects of cisplatin but increases mutagenesis.

  2019cites this paper
• Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.

  2019cites this paper
• Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis.

  2019cites this paper
• Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand

  2019cites this paper
• Chk1 phosphorylated at serine 345 is a predictor of early local recurrence and radio-resistance in breast cancer

  2018cites this paper
• Radio-sensitizing effects of VE-821 and beyond: Distinct phosphoproteomic and metabolomic changes after ATR inhibition in irradiated MOLT-4 cells

  2018cites this paper